Market cap
$7.45B

Amneal Pharmaceuticals Inc. (AMRX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for AMRX, including 9 press releases and news items, 3 SEC filings and 1 earnings update. The most recent was published Nov 10, 2026.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

AMRX rankings

Financial highlights

Full financials
Revenue, TTM
$3.20B
Revenue growth
+8.9%
Net income, TTM
$133.30M
Net margin
4.2%
Free cash flow, TTM
$88.19M
Cash
$157.40M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks46+500%
2026-05-24: 02026-05-31: 32026-06-07: 02026-06-14: 12026-06-21: 02026-06-28: 22026-07-05: 12026-07-12: 12026-07-19: 02026-07-26: 32026-08-02: 22026-08-09: 112026-08-16: 02026-08-23: 12026-08-30: 22026-09-06: 12026-09-13: 22026-09-20: 22026-09-27: 02026-10-04: 12026-10-11: 02026-10-18: 12026-10-25: 02026-11-01: 72026-11-08: 52026-11-15: 0
2026-05-242026-11-15
Mix2290d
  • Other10(45%)
  • Insider4(18%)
  • SEC Filings4(18%)
  • Analyst2(9%)
  • Earnings2(9%)
Activity · 52 weeks11056 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

AMRX FAQ

10 questions
  • What does Amneal Pharmaceuticals Inc. do?
    Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of...
  • What is the latest news on AMRX?
    In the last 30 days Quantisnow tracked 13 wire items for AMRX: 9 press releases and news items, 3 SEC filings and 1 earnings update. The most recent was published on November 10, 2026.
  • What is AMRX revenue?
    Amneal Pharmaceuticals Inc. (AMRX) reported $3.20B of revenue for the twelve months ended Sep 30, 2026. That is up 8.9% from the year before. Revenue for fiscal 2025 was $3.02B.
  • Is AMRX profitable?
    Yes. Amneal Pharmaceuticals Inc. earned $133.30M in net income for the twelve months ended Sep 30, 2026, a net margin of 4.2%.
  • How much cash and debt does AMRX have?
    Amneal Pharmaceuticals Inc. reported $157.40M in cash and cash equivalents and $2.94B of debt on its most recent balance sheet in SEC filings.
  • Where does AMRX stock trade?
    Amneal Pharmaceuticals Inc. (AMRX) is listed on NASDAQ.
  • What sector and industry is AMRX in?
    Amneal Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about AMRX?
    Across the last 7 analyst actions on Amneal Pharmaceuticals Inc., there were 2 upgrades and 0 downgrades. The most recent action was from Oppenheimer: Outperform with a $27.00 price target on 2026-09-23. Recent price targets range from $9.00 to $27.00.
  • What companies are similar to AMRX?
    Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare AMRX side-by-side with any of them on Quantisnow.
  • How can I track AMRX on Quantisnow?
    Quantisnow aggregates Amneal Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMRX to receive live email and push alerts on every new disclosure.